TABLE 5.
Antibody seroconversion to rotavirus VP4 and VP7 proteins by an EBA
| Serotypes of infecting virus (no. of samples) | No. of children showing seroconversion to the indicated protein and epitope (GMT)a
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| VP7 epitope
|
VP4 epitope
|
||||||||
| 5E8 (G1) | 2F1 (G2) | 4F8 (G3) | 2A4 (G1, G3) | Total [%] | 1A10 (P1A) | 1E4 (P1A, P2A) | YO-2C2 (P1A, P2A) | Total [%] | |
| G3, P1A (25) | 6 (56) | 3 (126) | 9 (400) | 5 (114) | 14 [56] | 8 (109) | 15 (87) | 2 (141) | 17 [68] |
| G1, P1A (12) | 1 (50) | 2 (71) | 6 (252) | 1 (50) | 8 [67] | 7 (149) | 4 (84) | 2 (50) | 9 [75] |
| Total (37) | 7 (55) | 5 (100) | 15 (333) | 6 (99) | 22 [59] (152) | 15 (126) | 19 (80) | 4 (84) | 26 [70] (96) |
a
The GMT was calculated from the convalescent-phase serum titers of the subjects whose sera seroconverted. The highest titer was used when there were seroconversions to more than one epitope. None of the serum samples competed with MAbs 2C9 (G1 specific), ST-2G7 (G4 specific), RV5:2 (P1B specific), or HS6 (P2A specific). The viruses used as antigens were as follows: Wa for MAbs 5E8, 2C9, 1A10, and 1E4; S2 for MAbs 2F1 and RV5:2; Price for MAbs 4F8, 2A4, and YO-2C2; and ST3 for MAbs ST-2G7 and HS6.